结肠癌肿瘤、免疫与微生物组整合图谱
本队列研究对348例原发性结肠癌患者的新鲜冷冻样本进行多组学分析,涵盖RNA、全外显子、深度T细胞受体和16S细菌rRNA基因测序,并辅以肿瘤全基因组测序。研究发现免疫常数排斥(Immunologic Constant of Rejection)特征优于常规预后分子标志物,微生物组特征(以Ruminococcus bromii驱动)与良好结局相关,二者组合的复合评分mICRoScore可识别生存概率极佳的患者组。
要点
- 免疫常数排斥基因表达特征可捕捉克隆扩增的肿瘤富集T细胞克隆,预后价值优于共识分子亚型和微卫星不稳定分类。
- 遗传免疫编辑定量(新抗原数量低于预期)进一步细化免疫常数排斥的预后价值。
- 微生物组特征(由Ruminococcus bromii驱动)与良好结局相关,与免疫常数排斥组合的mICRoScore可识别生存极佳患者组。
核心结论
- 免疫常数排斥特征优于常规预后分子标志物,遗传免疫编辑可细化其预后价值,微生物组特征与良好结局相关,mICRoScore可识别生存概率极佳的患者组。
研究设计与样本
- 本队列研究对348例原发性结肠癌患者的新鲜冷冻样本进行综合基因组分析,包括肿瘤与配对健康结肠组织的RNA、全外显子、深度T细胞受体和16S细菌rRNA基因测序,并辅以肿瘤全基因组测序以进一步表征微生物组。
主要发现
- 免疫常数排斥特征可捕捉克隆扩增的肿瘤富集T细胞克隆,且优于共识分子亚型和微卫星不稳定分类等常规预后分子标志物。
- 遗传免疫编辑定量(新抗原数量低于预期)进一步细化免疫常数排斥的预后价值。
- 微生物组特征由Ruminococcus bromii驱动,与良好结局相关。
- 结合微生物组特征与免疫常数排斥开发的复合评分mICRoScore经开发与验证,可识别生存概率极佳的患者组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The lack of multi-omics cancer datasets with extensive follow-up information hinders the identification of accurate biomarkers of clinical outcome. In this cohort study, we performed comprehensive genomic analyses on fresh-frozen samples from 348 patients affected by primary colon cancer, encompassing RNA, whole-exome, deep T cell receptor and 16S bacterial rRNA gene sequencing on tumor and matched healthy colon tissue, complemented with tumor whole-genome sequencing for further microbiome characterization. A type 1 helper T cell, cytotoxic, gene expression signature, called Immunologic Constant of Rejection, captured the presence of clonally expanded, tumor-enriched T cell clones and outperformed conventional prognostic molecular biomarkers, such as the consensus molecular subtype and the microsatellite instability classifications. Quantification of genetic immunoediting, defined as a lower number of neoantigens than expected, further refined its prognostic value. We identified a microbiome signature, driven by Ruminococcus bromii, associated with a favorable outcome. By combining microbiome signature and Immunologic Constant of Rejection, we developed and validated a composite score (mICRoScore), which identifies a group of patients with excellent survival probability. The publicly available multi-omics dataset provides a resource for better understanding colon cancer biology that could facilitate the discovery of personalized therapeutic approaches.
引用
- Roelands J, Kuppen PJK, Ahmed EI, et al. An integrated tumor, immune and microbiome atlas of colon cancer. Nat Med. 2023. PMID: 37202560. doi:10.1038/s41591-023-02324-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。